Literature DB >> 21540019

Current approaches to skin cancer management in organ transplant recipients.

Meena K Singh1, Jerry D Brewer.   

Abstract

Approximately 225,000 people are living with organ transplants in the United States. Organ transplant recipients have a greater risk of developing skin cancer, including basal cell carcinoma, squamous cell carcinoma, and malignant melanoma, with an approximately 250 times greater incidence of squamous cell carcinoma in certain transplant recipients, compared with the general population. Because skin cancers are the most common posttransplant malignancy, the resultant morbidity and mortality in these high-risk patients is quite significant. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21540019     DOI: 10.1016/j.sder.2011.02.003

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  4 in total

1.  Risk of Aggressive Skin Cancers After Kidney Retransplantation in Patients With Previous Posttransplant Cutaneous Squamous Cell Carcinomas: A Retrospective Study of 53 Cases.

Authors:  Emilie Ducroux; Clemmie Martin; Jan Nico Bouwes Bavinck; Evelyne Decullier; Anabelle Brocard; Marlies E Westhuis-van Elsäcker; Céleste Lebbé; Camille Francès; Emmanuel Morelon; Christophe Legendre; Pascal Joly; Jean Kanitakis; Denis Jullien; Sylvie Euvrard; Jacques Dantal
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  Squamous cell carcinoma of the spleen: A case report.

Authors:  Zhou Jiang; Fang Ma; Xianling Liu
Journal:  Oncol Lett       Date:  2018-07-06       Impact factor: 2.967

3.  Incomplete Excision of Cutaneous Squamous Cell Carcinoma; Systematic Review of the Literature.

Authors:  Roel E Genders; Nick Marsidi; Marlies Michi; Erik P Henny; Jelle J Goeman; Marloes S van Kester
Journal:  Acta Derm Venereol       Date:  2020-03-18       Impact factor: 3.875

4.  Advancing Survivors' Knowledge (ASK) about skin cancer study: study protocol for a randomized controlled trial.

Authors:  Casey L Daniel; Gregory T Armstrong; Robyn R Keske; Jessica A Davine; Aaron J McDonald; Kim M Sprunck-Harrild; Catherine Coleman; Sebastien J Haneuse; Ann C Mertens; Karen M Emmons; Ashfaq A Marghoob; Elena B Elkin; Stephen W Dusza; Leslie L Robison; Alan C Geller
Journal:  Trials       Date:  2015-03-24       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.